CRISPR-Based Gene Editing Market Size to Surge USD 13.39 Billion by 2034

The global CRISPR-based gene editing market size is expected to surge around USD 13.39 billion by 2034 increasing from USD 4.04 billion in 2024, with a CAGR of 13.00%.

Get a Free Sample Copy of the Report@ https://www.precedenceresearch.com/sample/5781

CRISPR-Based Gene Editing Market Key Highlights

• North America held the top position in the gene editing market with a 41.15% share in 2024.

• Asia Pacific is on track for accelerated growth at a CAGR of 15.18%.

• Kits and reagents were the leading products, comprising 77% of the market.

• The services category is witnessing growth momentum at 14.4% CAGR.

• Ex vivo editing represented the largest share among editing modalities at 53%.

• In vivo editing is expanding fastest, growing at 12.5% CAGR.

• CRISPR/Cas9 technology dominated with a 55% market share.

• CRISPR/Cas12 is poised for rapid growth at 12.3% CAGR.

• Therapeutic use was the most prominent application, holding 64.05% of the market.

• Agricultural and livestock applications are growing quickly, with a 14.3% CAGR.

• Biotech and pharmaceutical firms were the largest end-users at 42% share.

• The agricultural and livestock sector is gaining ground, growing steadily at 14.3% CAGR.

CRISPR-Based Gene Editing Market Growth Factors 

1. Rising Demand for Precision Medicine
   The growing need for targeted and personalized treatments is accelerating the adoption of CRISPR technology, which allows precise gene modifications to treat genetic disorders, cancers, and rare diseases.

2. Advancements in Biotechnology and Genomics
   Rapid developments in sequencing technologies, bioinformatics, and synthetic biology are enhancing the accuracy and scalability of CRISPR applications, fueling market growth.

3. Increasing R&D Investments
   Both public and private sectors are heavily investing in CRISPR research and therapeutic development, especially in areas like oncology, neurology, and inherited diseases.

4. Expanding Applications in Agriculture and Livestock
   CRISPR is being widely adopted to develop genetically modified crops with improved yields, pest resistance, and drought tolerance, as well as in livestock to enhance productivity and disease resistance.

5. Growing Collaborations and Licensing Agreements
   Strategic partnerships between biotech companies, research institutions, and pharmaceutical firms are fostering innovation, accelerating clinical trials, and expanding commercial access to CRISPR tools.

6. Supportive Government Initiatives and Funding
   Governments across the globe are promoting genome editing technologies through grants, subsidies, and regulatory support, encouraging wider adoption of CRISPR in healthcare and agriculture.

7. Emergence of AI and Computational Tools
   The integration of AI is streamlining CRISPR design, predicting off-target effects, and automating large-scale experiments—boosting the overall efficiency and reliability of gene editing processes.

8. Rising Prevalence of Genetic Disorders
   Increasing incidence of genetic diseases such as sickle cell anemia, cystic fibrosis, and Huntington’s disease is creating a strong demand for effective gene therapies based on CRISPR.

9. Commercialization of CRISPR-based Products
   Launches of CRISPR-based diagnostic kits, cell and gene therapies, and agricultural solutions are creating new revenue streams and expanding market reach globally.

10. Regulatory Advancements and Approvals
    Positive regulatory changes and accelerated approval pathways for gene therapies are improving the market outlook and fostering confidence in the technology.

Market Scope

Market Dynamics

Market Drivers

• Strong support from government agencies and research grants

• Expanding use of CRISPR in oncology and immunotherapy

• Demand for genetically modified crops and pest-resistant varieties

• Rising number of clinical trials and gene therapy approvals

Market Opportunities

• Tailored medicine through patient-specific gene therapies

• Rapid advancement in in vivo and ex vivo gene editing techniques

• Expansion in emerging economies with growing biotech industries

• New business models for CRISPR licensing and commercialization

Market Challenges

• Safety concerns with long-term effects of edited genes

• Technical issues related to delivery vectors for gene editing

• Varying regulatory environments affecting cross-border R&D

• Public hesitation and misinformation around gene editing

Regional Outlook

• The US remains the innovation hub for CRISPR development

• Europe emphasizes sustainable agriculture and medical applications

• Asia-Pacific is emerging as a growth engine with aggressive R&D funding

• Latin America and Africa are slowly adopting CRISPR with focus on agriculture

CRISPR-Based Gene Editing Market Companies

• CRISPR Therapeutics AG
• Agilent Technologies, Inc.
• Thermo Fisher Scientific, Inc.
• GeneCopoeia, Inc.
• Synthego Corporation
• System Biosciences LLC
• ToolGen, Inc.
• Rockland Immunochemicals, Inc.
• Horizon Discovery Group PLC
• Abcam, Inc.
• Applied StemCell, Inc.
• Cellecta, Inc.

Recent Developments

• In January 2025, scientists at the Institute of Cancer Research (ICR) in the UK developed a method for simultaneous activation, repression, and knockout of genes within a single cell by using CRISPR technology.
• In January 2025, researchers in the UK and the United States published a study about the use of prime-editing technology to insert recombinase sites into repetitive DNA sequences, exploring the human genome’s structural flexibility. This study allows scientists to create genomic rearrangements in human cell lines, including deletions, inversions, and translocations across all chromosomes.

Segment Covered in the Report

By Product

• Kits and Reagents
  • CRISPR Kits
  • Guide RNA
  • Enzymes
  • Other Reagents
• Services
  • Gene Editing Services
  • Contract Research Organizations (CROs)

By Gene Editing Modality

• Ex-Vivo Editing
• In-Vivo Editing

By Technology

• CRISPR/Cas9 Technology
• CRISPR/Cas12 Technology
• CRISPR/Cas13 Technology
• Base Editing
• Prime Editing
• Epigenetic Editing
• Others

By Application

• Therapeutic Applications
  • Gene Therapy
  • Cancer Therapy
  • Infectious Disease Treatment
  • Regenerative Medicine
• Agriculture and Livestock
  • Crop Improvement
  • Livestock Modifications
• Industrial Biotechnology
  • Microbial Engineering
  • Biomanufacturing

By End User

• Academic and Research Institutes
• Biotechnology and Pharmaceutical Companies
• Agricultural and Livestock Industry
• Hospitals and Clinics
• Contract Research Organizations (CROs)

By Geography

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Also Read: Vendor Neutral Archive and PACS Market

Ready for more? Dive into the full experience on our website@ https://www.precedenceresearch.com/

akshay dhamal